Gland Pharma Limited vs Ajanta Pharma Limited
An objective side-by-side of GLAND and AJANTPHARM, both in Pharmaceuticals - Indian - Formulations: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: GLAND Mar 2026 · AJANTPHARM Jun 2026
At a glance
- Gland Pharma Limited is the larger company by market value, about 1.1 times the size of Ajanta Pharma Limited.
- On trailing earnings, Ajanta Pharma Limited trades at the lower P/E (39.0 against 47.2).
- Ajanta Pharma Limited earns the higher return on equity (25.1% against 9.9%).
- Over three years Ajanta Pharma Limited has grown profits faster (21% a year against 8%).
- Over the past year the share prices returned +45.8% (GLAND) and +38.9% (AJANTPHARM).
| Metric | Gland Pharma GLAND |
Ajanta Pharma AJANTPHARM |
|---|---|---|
| Size and price | ||
| Market cap | ₹48,503 Cr | ₹44,262 Cr |
| Share price | ₹2,940 | ₹3,542 |
| Valuation | ||
| P/E | 47.20 | 38.99 |
| P/B | 4.68 | 9.78 |
| EV/EBITDA | 29.94 | 30.36 |
| PEG | 5.90 | 1.86 |
| Dividend yield | 0.6% | 0.8% |
| Profitability | ||
| ROE | 9.9% | 25.1% |
| ROCE | 15.0% | 32.0% |
| Operating margin | 25.3% | 25.4% |
| Sales (TTM) | ₹6,431 Cr | ₹5,777 Cr |
| Net profit (TTM) | ₹1,028 Cr | ₹1,135 Cr |
| Growth | ||
| Latest quarter sales YoY | +22.3% | +24.8% |
| Latest quarter profit YoY | +96.7% | +30.9% |
| Sales CAGR 3Y | +21.0% | +13.0% |
| Profit CAGR 3Y | +8.0% | +21.0% |
| Sales CAGR 5Y | +13.0% | +14.0% |
| Profit CAGR 5Y | +1.0% | +10.0% |
| Financial strength | ||
| Debt/Equity | 0.03 | 0.06 |
| Interest cover | 36.26 | 77.57 |
| Ownership | ||
| Promoter holding | 51.8% | 66.2% |
| Promoter change (4 qtrs) | -0.06 pp | -0.01 pp |
| Price performance | ||
| Return 1M | +4.26% | -3.18% |
| Return 3M | +34.46% | +11.05% |
| Return 1Y | +45.76% | +38.93% |
| Return YTD | +70.74% | +27.92% |
| Technical condition | ||
| Technical score | 83 | 62 |
| RS rating (1-99) | 92.00 | 78.00 |
| % vs 200-DMA | +39.97% | +15.64% |
| RSI (14) | 57.29 | 51.54 |
| % from 52-week high | -3.35% | -6.69% |
